Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 1 – The Novartis case | Orphan Drugs Industry Advisory & Intelligence

Orphan Drugs Industry Advisory & Intelligence

Skip to content

Home
About us
Free demo
ODI Advisory
ODI Insider | Oncology
ODI Insider | Rare Diseases
ODI | Databases
Press, Articles & News

Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 2 – The Pfizer case →

Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 1 – The Novartis case

Posted on April 26, 2016 by christian@orphandrugsindustry.com

Link to article

Advertisements

Share this:

Twitter
Facebook
Google
LinkedIn
Print
Reddit
Tumblr
Email
Pinterest
Pocket

This entry was posted in Pulse and tagged Big pharma, Orphan drugs, Rare diseases. Bookmark the permalink.

Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 2 – The Pfizer case →

Advertisements

Search for:
Archives
- May 2016
- April 2016
Meta
- Register
- Log in

Click to contact us
Visitors
- 3,330 hits

Headquarter
1, rue Roch ar Ruguel
29680 Roscoff, France
Tel: +33 (0)2 98 88 63 72

Orphan Drugs Industry Advisory & Intelligence

Send to Email Address Your Name Your Email Address

Cancel

Post was not sent - check your email addresses!

Email check failed, please try again

Sorry, your blog cannot share posts by email.

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Our Cookie Policy